Number of US ALS cases expected to increase 10% this decade: Study

The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the…

Healthcare costs increase as ALS progresses, Biogen study finds

Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease progresses, going from about $31,000 per year in the early disease stage to $122,000 per year in the late stage, a study…

FDA Approves Dosing Tiglutik Via Feeding Tube for ALS Patients

The U.S. Food and Drug Administration has agreed to expand Tiglutik, a liquid oral form of riluzole, to include giving it via a feeding tube to treat amyotrophic lateral sclerosis (ALS), ITF Pharma, the company marketing Tiglutik, announced. The approval of administering the therapy via percutaneous endoscopic…

Tiglutik, Liquid Form of Riluzole, Now Available in US for ALS Treatment

Tiglutik, an oral suspension of riluzole, is now available as a treatment for amyotrophic lateral sclerosis (ALS) in the U.S., ITF Pharma, the therapy’s developer and a subsidiary of Italfarmaco, recently announced. Rilutek (riluzole, marketed by Sanofi), has been available in the U.S. as 50 mg tablets…